HRAS and glioblastoma: Subsequently, we selected 0.2, 0.4 and 0.8 μM of Chr-A in the U251 cells and 0.2, 0.6 and 1.8 μM of Chr-A in the U87-MG cells to investigate the anti-glioblastoma efficacy of Chr-A and the possible mechanisms.